Stock ROG ROCHE HOLDING AG
Add to a list
To use this feature you must be a member
Log inSign up

Roche Holding AG Stock

Equities

ROG

CH0012032048

Pharmaceuticals

Real-time Estimate Cboe Europe
Other stock markets
 03:27:42 2024-09-06 am EDT 		5-day change 1st Jan Change
274.45 CHF -0.63% Intraday chart for Roche Holding AG -4.46% +12.23%
09:13am ROCHE HOLDINGS AG : Berenberg sticks Neutral ZD
08:28am ROCHE HOLDINGS AG : JP Morgan reiterates its Sell rating ZD
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
limited-time offer
Enjoy this offer
* See conditions on site

Valuation: Roche Holding AG

Capitalization 222B 264B P/E ratio 2024 *
16.5x
P/E ratio 2025 * 14.2x
Enterprise value 238B 282B EV / Sales 2024 *
3.91x
EV / Sales 2025 * 3.62x
Free-Float
88.01%
Yield 2024 *
3.57%
Yield 2025 * 3.66%
More valuation ratios * Estimated data

Chart: Roche Holding AG

Dynamic Chart

Latest news: Roche Holding AG

ROCHE HOLDINGS AG : Berenberg sticks Neutral ZD
ROCHE HOLDINGS AG : JP Morgan reiterates its Sell rating ZD
Swiss Equities Remain in the Red Amid Regional Retreat MT
Roche: new positive data for fenebrutinib CF
Roche's Investigational Multiple Sclerosis Drug Shows Disease Activity Suppression in Mid-stage Trial MT
Roche's Fenebrutinib Demonstrates Near- Complete Suppression of Disease Activity and Disability Progression for Up to 48 Weeks in Patients with Relapsing Multiple Sclerosis CI
ROCHE HOLDINGS AG : JP Morgan maintains a Sell rating ZD
ROCHE HOLDINGS AG : Bernstein maintains a Buy rating ZD
Swiss Equities Close in the Red; Roche Sheds 1% MT
Roche: approval from Brussels for HPN CF
Roche's Paroxysmal Nocturnal Haemoglobinuria Treatment Wins EU Approval MT
Roche?s PiaSky Approves in the Eu as the First Monthly Subcutaneous Treatment for People with PNH CI
Roche Gets EU Approval for Blood Disorder Injection PiaSky DJ
More news

Last Transcript: Roche Holding AG

Logo Roche Holding AG
Roche Holding AG, Q2 2024 Earnings Call, Jul 25, 2024
More transcripts

Analysts' recommendations: Roche Holding AG

ROCHE HOLDINGS AG : Berenberg sticks Neutral ZD
ROCHE HOLDINGS AG : JP Morgan reiterates its Sell rating ZD
ROCHE HOLDINGS AG : JP Morgan maintains a Sell rating ZD
ROCHE HOLDINGS AG : Bernstein maintains a Buy rating ZD
ROCHE HOLDINGS AG : Deutsche Bank remains Neutral ZD
More recommendations

Press Releases: Roche Holding AG

New Data for Genentech’s Susvimo Demonstrates Sustained Efficacy in Two Serious Diabetic Eye Conditions BU
Genentech’s Vabysmo Showed Extended Durability, Continued Efficacy and a Consistent Safety Profile in Long-Term Diabetic Macular Edema (DME) Study BU
Genentech Announces Positive Phase I Results of Its Oral GLP-1 Receptor Agonist CT-996 for the Treatment of People With Obesity BU
Genentech to Reintroduce Susvimo for People With Wet Age-related Macular Degeneration (AMD) BU
FDA Approves Genentech’s Vabysmo Prefilled Syringe (PFS) for Three Leading Causes of Vision Loss BU
More press releases

News in other languages: Roche Holding AG

Aktien Schweiz schwächer - Konjunkturskepsis belastet Kurse
Aktien Schweiz: Schwächer - Zurückhaltung vor US-Arbeitsmarktdaten
Aktien Schweiz Eröffnung: Weitere Verluste - Hoffnung auf Stabilisierung
Borsa svizzera: chiude in ribasso, SMI -1,39%
Roche : nouvelles données positives pour le fenebrutinib
More news

Quotes and Performance

1 day-0.76%
1 week-3.22%
Current month-3.83%
1 month+2.30%
3 months+16.98%
6 months+17.68%
Current year+12.97%
More quotes

Course Extremes

1 week
274.40
Extreme 274.4
288.20
1 month
268.80
Extreme 268.8
288.20
Current year
212.90
Extreme 212.9
288.20
1 year
212.90
Extreme 212.9
288.20
3 years
212.90
Extreme 212.9
404.20
5 years
212.90
Extreme 212.9
404.20
10 years
206.35
Extreme 206.35
404.20
More quotes

Managers and Directors: Roche Holding AG

Director TitleAgeSince
Thomas Schinecker CEO
 Chief Executive Officer 49 02-12-31
Alan Hippe DFI
 Director of Finance/CFO 57 11-03-31
Levi Garraway CTO
 Chief Tech/Sci/R&D Officer - -
Manager TitleAgeSince
André S. Hoffmann BRD
 Director/Board Member 66 95-12-31
Severin Schwan CHM
 Chairman 57 07-12-31
Bernard Poussot BRD
 Director/Board Member 72 15-03-02
More insiders

ETFs: Roche Holding AG

Name Weight AuM 1st Jan change Investor Rating
LYXOR DJ SWITZERLAND TITANS 30 (DR) UCITS ETF- CHF ETF Lyxor DJ Switzerland Titans 30 (DR) UCITS ETF- CHF
9.03% 121 M€ -.--% -
NOMURA NEXT FUNDS INTERNATIONAL EQUITY MSCI-KOKUSAI (YEN-HEDGED) ETF - JPY ETF Nomura NEXT FUNDS International Equity MSCI-KOKUSAI (Yen-Hedged) ETF - JPY
8.46% 18 M€ +7.76% -
BMO MSCI GENOMIC INNOVATION INDEX ETF - CAD ETF BMO MSCI Genomic Innovation Index ETF - CAD
4.67% 2 M€ -.--%
AMUNDI MSCI EUROPE EX UK UCITS ETF (C) - EUR ETF AMUNDI MSCI EUROPE EX UK UCITS ETF (C) - EUR
2.85% 6 M€ -.--% -
More ETFs: Roche Holding AG

Other Pharmaceuticals

Add to a list
Add to a list

0 selected

To use this feature you must be a member
Log inSign up
 Change 5d. change 1-year change 3-years change Capi. ($)
ROCHE HOLDING AG Stock Roche Holding AG
-0.78%-3.22%+8.78%-24.28%262B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
-3.55%-2.92%+63.52%+251.69%822B
NOVO NORDISK A/S Stock Novo Nordisk A/S
-1.36%-4.01%+33.76%+181.19%583B
JOHNSON & JOHNSON Stock Johnson & Johnson
-1.42%+0.46%+2.68%-5.74%397B
ABBVIE INC. Stock AbbVie Inc.
-2.11%-1.19%+32.01%+72.78%341B
MERCK & CO., INC. Stock Merck & Co., Inc.
+2.41%+0.96%+10.31%+53.49%301B
ASTRAZENECA PLC Stock AstraZeneca PLC
+0.12%-5.53%+16.80%+47.37%256B
NOVARTIS AG Stock Novartis AG
-1.21%-2.95%+12.67%+18.64%236B
AMGEN INC. Stock Amgen Inc.
-1.90%-2.01%+27.70%+43.29%174B
PFIZER, INC. Stock Pfizer, Inc.
+0.42%-0.73%-19.42%-39.13%162B
Average -0.27%-2.11%+18.88%+59.93% 353.35B
Weighted average by Cap. -0.27%-2.29%+27.80%+102.57%
See all sector performances

Financials

2024 *2025 *
Net sales 60.78B 72.21B 64.19B 76.26B
Net income 13.04B 15.49B 15.09B 17.93B
Net Debt 15.22B 18.08B 10.03B 11.92B
More financial data * Estimated data

Company Profile

Logo Roche Holding AG
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Employees
103,605
Sector
Pharmaceuticals
Calendar
2024-09-13 - European Association for the Study of Diabetes Meeting
Related indices
SMI , STOXX Europe 600 Index (EUR)
More about the company

Quotes

Date Price Change Volume
24-09-06 274.60 CHF -0.58% 46,953
24-09-05 276.20 CHF -1.07% 1,704,249
24-09-04 279.20 CHF -0.85% 2,499,132
24-09-03 281.60 CHF -2.12% 1,417,618
24-09-02 287.70 CHF +0.17% 1,382,103

Delayed Quote Swiss Exchange, September 05, 2024 at 11:30 am EDT

More quotes

Income Statement and Estimates

More financial data

Ratings

Trading Rating
Investor Rating
ESG Refinitiv
A+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
19
Last Close Price
276.20CHF
Average target price
298.00CHF
Spread / Average Target
+7.89%
Consensus
Profit revisions
Estimate revisions

Quarterly earnings, Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. ROG Stock
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW